Outcomes of thrombotic thrombocytopenic purpura patients submitted to therapeutic plasma exchange in a single center in Brazil

被引:1
作者
Terra, Patricia Oliveira Cunha [1 ,2 ]
De Santis, Gil Cunha [1 ,2 ]
Prado Junior, Benedito de Pina Almeida [1 ,2 ]
Oliveira, Luciana Correa [1 ,2 ]
机构
[1] Univ Sao Paulo, Dept Med Imaging Hematol & Oncol, Ribeirao Preto Med Sch, Sao Paulo, Brazil
[2] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Sao Paulo, Brazil
关键词
nic purpura; Hospital mortality; Plasma exchange; Hemolysis; Focal neurological deficit; Immune thrombotic thrombocytope; TTP; MICROANGIOPATHIES; VALIDATION; CONSENSUS; FEATURES; REGISTRY;
D O I
10.1016/j.htct.2023.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by acute systemic microvascular thrombosis and is associated with a high morbidity and mortality, especially in delayed diagnosis (later than 6-7 days from symptoms). iTTP data in Brazil is scarce, so we aimed to characterize the clinical presentation and identify predictors of death risk in patients with this disease in Brazil. Methods: In this single-center retrospective study the patients who underwent therapeutic plasma exchange (TPE) for presumptive or confirmed iTTP were evaluated regarding the epidemiological, clinical, laboratorial characteristics and management. Results: A total of 50 patients (90 % female), with median age (IQR) of 34.1 (27-47) years, were enrolled, of which 12(24%) died. The most frequent symptoms were neurological (96 %), bleeding (76 %), gastrointestinal (52 %), fever (38 %), and cardiovascular (22 %). Neurological focal deficit and cardiovascular symptoms were more frequently observed in the non-survivor group (P = 0.0019 and P = 0.007, respectively). The mean SD number of days from beginning of symptoms to first TPE was 12.22 7.91. We identified an association regarding mortality rate with a score MITS >= 2 points (P = 0.04), a higher indirect bilirubin (P = 0.0006), a higher number of transfused red blood cell units (P = 0.025), and platelet transfusion (P = 0.027). Conclusion: Delayed diagnosis appears to be associated with a higher frequency of neurological symptoms and mortality. Intensity of hemolysis and signs of organ ischemia, such as cardiovascular symptoms and focal neurological deficit, are indicators of death risk. (c) 2023 Associa & ccedil;& atilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:S24 / S31
页数:8
相关论文
共 50 条
  • [41] Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura
    Owens, MR
    Sweeney, JD
    Tahhan, RH
    Fortkolt, P
    [J]. JOURNAL OF CLINICAL APHERESIS, 1995, 10 (04) : 178 - 182
  • [42] Understanding therapeutic targets in thrombotic thrombocytopenic purpura
    Joly, Berangere S.
    Vanhoorelbeke, Karen
    Veyradier, Agnes
    [J]. INTENSIVE CARE MEDICINE, 2017, 43 (09) : 1398 - 1400
  • [43] Thrombotic thrombocytopenic purpura: A diagnostic and therapeutic challenge
    Kwaan, HC
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (06) : 615 - 624
  • [44] Pulmonary involvement in patients with thrombotic thrombocytopenic purpura
    Nokes, Timothy
    George, James N.
    Vesely, Sara K.
    Awab, Ahmed
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (02) : 156 - 163
  • [45] Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
    van de Louw, Andry
    Mariotte, Eric
    Darmon, Michael
    Cohrs, Austin
    Leslie, Douglas
    Azoulay, Elie
    [J]. PLOS ONE, 2021, 16 (08):
  • [46] Survival and relapse in patients with thrombotic thrombocytopenic purpura
    Hovinga, Johanna A. Kremer
    Vesely, Sara K.
    Terrell, Deirdra R.
    Laemmle, Bernhard
    George, James N.
    [J]. BLOOD, 2010, 115 (08) : 1500 - 1511
  • [47] Impact of Acute Coronary Syndrome on Clinical Outcomes in Patients With Thrombotic Thrombocytopenic Purpura
    Khalil, Fouad
    Ali, Mohammad
    Ellithi, Moataz
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [48] Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
    Michinori Kayashima
    Kazuya Sakai
    Kazuki Harada
    Jun Kanetake
    Masayuki Kubo
    Eriko Hamada
    Masaki Hayakawa
    Kinta Hatakeyama
    Masanori Matsumoto
    [J]. International Journal of Hematology, 2021, 114 : 415 - 423
  • [49] Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura
    Azoulay, Elie
    Bauer, Philippe R.
    Mariotte, Eric
    Russell, Lene
    Knoebl, Paul
    Martin-Loeches, Ignacio
    Pene, Frederic
    Puxty, Kathryn
    Povoa, Pedro
    Barratt-Due, Andreas
    Garnacho-Montero, Jose
    Wendon, Julia
    Munshi, Laveena
    Benoit, Dominique
    von Bergwelt-Baildon, Michael
    Maggiorini, Marco
    Coppo, Paul
    Cataland, Spero
    Veyradier, Agnes
    Van de Louw, Andry
    [J]. INTENSIVE CARE MEDICINE, 2019, 45 (11) : 1518 - 1539
  • [50] Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura
    Moore, J. C.
    Arnold, D. M.
    Leber, B. F.
    Clare, R.
    Molnar, G. J.
    Kelton, J. G.
    [J]. VOX SANGUINIS, 2007, 93 (02) : 173 - 175